Amivantamab (RYBREVANT)
Criteria for Use
December 2024

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the *PBM INTRAnet* site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive Amivantamab.

- ☐ Active or untreated brain metastases
- ☐ Unable to tolerate pre-medications^
- ☐ Pregnancy or lactating

^ acetaminophen + diphenhydramine + dexamethasone or methylprednisolone

Inclusion Criteria

ONE of the following criteria must be met:

- ☐ Locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutation whose disease progressed on or after platinum-based chemotherapy
- ☐ In combination with carboplatin and pemetrexed for first-line therapy of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutation
- ☐ In combination with Lazertinib for first-line therapy of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations^
- ☐ In combination with carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations in patients who progressed on or after an EGFR TKI

^ Give anticoagulant prophylaxis to prevent VTE during first 4 months of combination with lazertinib

Additional Inclusion Criteria (if applicable)

- ☐ For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 3 months after stopping treatment

Additional Inclusion Criteria

All of the following criteria must be met.

- ☐ Screened for Hepatitis B and Hepatitis C and managed appropriately by provider as needed including a risk/benefit discussion.
- ☐ Care is provided by a VA/VA Community Care oncology provider
- ☐ Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented

Other Justification

☐ _____

Prepared: February 2022; Updated December 2024. Contact: Mark C. Geraci, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)